American Assets Inc. bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 5,000 shares of the specialty pharmaceutical company's stock, valued at approximately $557,000. Jazz Pharmaceuticals comprises about 0.2% of American Assets Inc.'s investment portfolio, making the stock its 13th largest holding.
Other hedge funds also recently bought and sold shares of the company. Private Advisor Group LLC boosted its stake in shares of Jazz Pharmaceuticals by 6.5% during the 1st quarter. Private Advisor Group LLC now owns 3,159 shares of the specialty pharmaceutical company's stock worth $380,000 after acquiring an additional 192 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in Jazz Pharmaceuticals by 45.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 15,888 shares of the specialty pharmaceutical company's stock valued at $1,913,000 after buying an additional 4,939 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in Jazz Pharmaceuticals by 17.1% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 2,418 shares of the specialty pharmaceutical company's stock valued at $291,000 after buying an additional 353 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at approximately $701,000. Finally, Russell Investments Group Ltd. grew its holdings in Jazz Pharmaceuticals by 8.8% in the 1st quarter. Russell Investments Group Ltd. now owns 264,473 shares of the specialty pharmaceutical company's stock valued at $31,848,000 after buying an additional 21,368 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.
JAZZ traded up $0.70 during trading on Tuesday, hitting $127.82. The company's stock had a trading volume of 42,154 shares, compared to its average volume of 672,229. The firm's 50 day moving average price is $110.64 and its two-hundred day moving average price is $109.79. The company has a quick ratio of 2.02, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The stock has a market capitalization of $7.89 billion, a price-to-earnings ratio of 17.90, a price-to-earnings-growth ratio of 1.55 and a beta of 0.57.
In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company's stock, valued at $1,573,707.30. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company's stock.
A number of analysts have issued reports on JAZZ shares. Royal Bank of Canada raised their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a report on Wednesday, October 23rd. Robert W. Baird decreased their price objective on Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating on the stock in a report on Thursday, August 1st. Piper Sandler decreased their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an "overweight" rating on the stock in a report on Thursday, August 1st. Wells Fargo & Company decreased their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating on the stock in a report on Thursday, August 1st. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $175.00.
Check Out Our Latest Stock Report on Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.